Beruzatatug pelitecan vs Patritumab Deruxtecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: HER3 · full Non-Small Cell Lung Cancer pipeline

Beruzatatug pelitecan

Developed by BioNTech under a licence from MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT06107686 (registry estimate)

No aligned efficacy figure on record for this race.

Patritumab Deruxtecan

Developed by Daiichi Sankyo and partners

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
Weak signal

NCT05865990 · Phase 2 · completed

The study used a single-arm, open-label design with no placebo or active comparator, so responses cannot be reliably separated from the natural course of disease or other factors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: August 2029 · NCT07286149 (registry estimate)

Reported efficacy

Efficacy: Local determination of intracranial objective response rate (ORR-IC) in cohort 1 and cohort 2. (From baseline to the date of first documented progression, death from any cause, or treatment discontinuation from any reason, whichever came first, assessed up to 12 months); Efficacy: Overall survival (OS) rate at 3 months in cohort 3. (From baseline up to 3 months): LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001) (met)

Result source: NCT05865990

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBeruzatatug pelitecanPatritumab Deruxtecan
PFS, median—Trial running · NCT07416994—Trial running · NCT05338970
OS, median—Trial running · NCT07416994—Trial running · NCT05338970
ORR—Trial running · NCT07416994—Trial running · NCT05338970
Duration of response, median—Trial running · NCT07416994—Trial running · NCT05338970

PFS, median

Beruzatatug pelitecan
—Trial running · NCT07416994
Patritumab Deruxtecan
—Trial running · NCT05338970

OS, median

Beruzatatug pelitecan
—Trial running · NCT07416994
Patritumab Deruxtecan
—Trial running · NCT05338970

ORR

Beruzatatug pelitecan
—Trial running · NCT07416994
Patritumab Deruxtecan
—Trial running · NCT05338970

Duration of response, median

Beruzatatug pelitecan
—Trial running · NCT07416994
Patritumab Deruxtecan
—Trial running · NCT05338970
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Beruzatatug pelitecan: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Patritumab Deruxtecan
LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001) NCT05865990 · Phase 2 · design grade: weak · publication or press release

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: HER3 · full HR+/HER2- Metastatic Breast Cancer pipeline

Beruzatatug pelitecan

Developed by BioNTech under a licence from MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 3 in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT06107686 (registry estimate)

No aligned efficacy figure on record for this race.

Patritumab Deruxtecan

Developed by Daiichi Sankyo and partners

Phase 3 in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
Weak signal

NCT02980341 · Phase 1/2 · completed

The study was labeled randomized, but it was open-label and contained only patritumab deruxtecan dose-escalation, dose-finding, and dose-expansion cohorts, with no placebo or active comparator. Although tumor response was assessed using RECIST and results were posted, there was no controlled primary comparison to establish the drug’s effect.

Next expected readout: April 2027 · NCT04965766 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBeruzatatug pelitecanPatritumab Deruxtecan
PFS, median—Trial running · NCT074614547.2bn 60NCT04699630
2 other results
OS, median—Trial running · NCT07461454—Trial running · NCT07060807
ORR—Trial running · NCT0746145435%bn 60NCT04699630
2 other results
Clinical benefit rate—Trial running · NCT0746145448.3%bn 60NCT04699630
2 other results

PFS, median

Beruzatatug pelitecan
—Trial running · NCT07461454
Patritumab Deruxtecan
7.2bn 60NCT04699630
2 other results

OS, median

Beruzatatug pelitecan
—Trial running · NCT07461454
Patritumab Deruxtecan
—Trial running · NCT07060807

ORR

Beruzatatug pelitecan
—Trial running · NCT07461454
Patritumab Deruxtecan
35%bn 60NCT04699630
2 other results

Clinical benefit rate

Beruzatatug pelitecan
—Trial running · NCT07461454
Patritumab Deruxtecan
48.3%bn 60NCT04699630
2 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Beruzatatug pelitecan: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Beruzatatug pelitecan: 0 of 4 rows · Patritumab Deruxtecan: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPatritumab Deruxtecan
Dropout rate
n/a: no completion milestone8.0 mg/kga
NCT02980341 · Phase 1/2
show 11 more results
n/a: no completion milestone6.4 mg/kg
NCT02980341 · Phase 1/2
—6.4 mg/kg
NCT02980341 · Phase 1/2
—6.4 mg/kg
NCT02980341 · Phase 1/2
—6.4 mg/kg
NCT02980341 · Phase 1/2
n/a: no completion milestone4.8 mg/kg
NCT02980341 · Phase 1/2
—4.8 mg/kg
NCT02980341 · Phase 1/2
n/a: no completion milestone3.2 mg/kg
NCT02980341 · Phase 1/2
n/a: no completion milestone1.6 mg/kg
NCT02980341 · Phase 1/2
n/a: no completion milestonePart A
NCT04699630 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePart B
NCT04699630 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePart Z
NCT04699630 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
33.3%8.0 mg/kga
NCT02980341 · Phase 1/2
show 11 more results
13.3%6.4 mg/kg
NCT02980341 · Phase 1/2
—6.4 mg/kg
NCT02980341 · Phase 1/2
—6.4 mg/kg
NCT02980341 · Phase 1/2
—6.4 mg/kg
NCT02980341 · Phase 1/2
6.7%4.8 mg/kg
NCT02980341 · Phase 1/2
—4.8 mg/kg
NCT02980341 · Phase 1/2
0%3.2 mg/kg
NCT02980341 · Phase 1/2
0%1.6 mg/kg
NCT02980341 · Phase 1/2
21.7%Part A
NCT04699630 · Phase 2 · registry result, not featured evidence
5%Part B
NCT04699630 · Phase 2 · registry result, not featured evidence
0%Part Z
NCT04699630 · Phase 2 · registry result, not featured evidence
Serious AEs
33.3%8.0 mg/kga
NCT02980341 · Phase 1/2
show 11 more results
60%6.4 mg/kg
NCT02980341 · Phase 1/2
38.7%6.4 mg/kg
NCT02980341 · Phase 1/2
33.3%6.4 mg/kg
NCT02980341 · Phase 1/2
25.8%6.4 mg/kg
NCT02980341 · Phase 1/2
20%4.8 mg/kg
NCT02980341 · Phase 1/2
30.3%4.8 mg/kg
NCT02980341 · Phase 1/2
33.3%3.2 mg/kg
NCT02980341 · Phase 1/2
33.3%1.6 mg/kg
NCT02980341 · Phase 1/2
20%Part A
NCT04699630 · Phase 2 · registry result, not featured evidence
17.5%Part B
NCT04699630 · Phase 2 · registry result, not featured evidence
23.8%Part Z
NCT04699630 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
8.0 mg/kga
nausea 100%
alopecia 66.7%
decreased appetite 66.7%
NCT02980341 · Phase 1/2
show 11 more results
6.4 mg/kg
nausea 93.3%
white blood cell count decreased 93.3%
neutrophil count decreased 86.7%
NCT02980341 · Phase 1/2
6.4 mg/kg
nausea 80.6%
anaemia 61.3%
decreased appetite 48.4%
NCT02980341 · Phase 1/2
6.4 mg/kg
nausea 71.4%
platelet count decreased 52.4%
stomatitis 47.6%
NCT02980341 · Phase 1/2
6.4 mg/kg
nausea 80.6%
decreased appetite 58.1%
platelet count decreased 54.8%
NCT02980341 · Phase 1/2
4.8 mg/kg
nausea 73.3%
aspartate aminotransferase increased 66.7%
neutrophil count decreased 66.7%
NCT02980341 · Phase 1/2
4.8 mg/kg
nausea 66.7%
decreased appetite 54.5%
diarrhoea 45.5%
NCT02980341 · Phase 1/2
3.2 mg/kg
nausea 100%
stomatitis 100%
decreased appetite 66.7%
NCT02980341 · Phase 1/2
1.6 mg/kg
decreased appetite 66.7%
nausea 66.7%
vomiting 66.7%
NCT02980341 · Phase 1/2
nausea 55%
fatigue 48.3%
diarrhoea 43.3%
NCT04699630 · Phase 2 · registry result, not featured evidence
nausea 42.5%
fatigue 37.5%
neutrophil count decreased 32.5%
NCT04699630 · Phase 2 · registry result, not featured evidence
nausea 52.4%
diarrhoea 33.3%
neutrophil count decreased 33.3%
NCT04699630 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Patritumab Deruxtecan

ORR 50% (n=6)8.0 mg/kg
event count · % of participants
No placebo or comparator arm
Objective response rate (ORR)
NCT02980341 · Phase 1/2 · converted to % from 3 Participants as posted
show 8 more results
46.7% (n=15)*6.4 mg/kg
Objective response rate (ORR)
NCT02980341 · Phase 1/2 · converted to % from 7 Participants as posted
16.1% (n=31)*6.4 mg/kg
Objective response rate (ORR)
NCT02980341 · Phase 1/2 · converted to % from 5 Participants as posted
33.3% (n=21)*6.4 mg/kg
Objective response rate (ORR)
NCT02980341 · Phase 1/2 · converted to % from 7 Participants as posted
16.1% (n=31)*6.4 mg/kg
Objective response rate (ORR)
NCT02980341 · Phase 1/2 · converted to % from 5 Participants as posted
33.3% (n=15)*4.8 mg/kg
Objective response rate (ORR)
NCT02980341 · Phase 1/2 · converted to % from 5 Participants as posted
33.3% (n=33)*4.8 mg/kg
Objective response rate (ORR)
NCT02980341 · Phase 1/2 · converted to % from 11 Participants as posted
33.3% (n=3)*3.2 mg/kg
Objective response rate (ORR)
NCT02980341 · Phase 1/2 · converted to % from 1 Participants as posted
0% (n=3)*1.6 mg/kg
Objective response rate (ORR)
NCT02980341 · Phase 1/2 · converted to % from 0 Participants as posted
ORR 35% (n=60)
responder rate · % of participants
No placebo or comparator arm
NCT04699630 · Phase 2 · registry result, not featured evidence
show 2 more results
5% (n=40)
NCT04699630 · Phase 2 · registry result, not featured evidence
4.8% (n=21)
NCT04699630 · Phase 2 · registry result, not featured evidence
PFS 6mo 43.3% (n=60) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT04699630 · Phase 2 · registry result, not featured evidence
show 2 more results
10% (n=40) @ 26wk
NCT04699630 · Phase 2 · registry result, not featured evidence
0% (n=21) @ 26wk
NCT04699630 · Phase 2 · registry result, not featured evidence
Duration of Response 7.5 months
time to event · months
No placebo or comparator arm
NCT04699630 · Phase 2 · registry result, not featured evidence
show 2 more results
3.6 months
NCT04699630 · Phase 2 · registry result, not featured evidence
4.3 months
NCT04699630 · Phase 2 · registry result, not featured evidence
PFS 7.2 months
time to event · months
No placebo or comparator arm
NCT04699630 · Phase 2 · registry result, not featured evidence
show 2 more results
2.6 months
NCT04699630 · Phase 2 · registry result, not featured evidence
1.4 months
NCT04699630 · Phase 2 · registry result, not featured evidence
Clinical Benefit 48.3% (n=60)
responder rate · % of participants
No placebo or comparator arm
NCT04699630 · Phase 2 · registry result, not featured evidence
show 2 more results
5% (n=40)
NCT04699630 · Phase 2 · registry result, not featured evidence
4.8% (n=21)
NCT04699630 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Beruzatatug pelitecan's landscape · Patritumab Deruxtecan's landscape